Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 22, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis

aTyr Pharma Announces Last Patient Visit in Phase 3 EFZO-FIT™ Study of Efzofitimod in Patients with Pulmonary Sarcoidosis
June 26, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes

aTyr Pharma to be Added to the Russell 2000® and Russell 3000® Indexes
June 04, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)

aTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung
May 20, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Present at Upcoming Investor Conferences

aTyr Pharma to Present at Upcoming Investor Conferences
May 19, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference
May 14, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
May 07, 2025 16:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
April 29, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
April 03, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma to Participate in April Investor Conferences
March 26, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

Next Page keyboard_arrow_right